These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 16932716)

  • 1. Is there a pharmacoeconomic argument supporting the use of tumor necrosis factor inhibitors in early rheumatoid arthritis?
    Kavanaugh A
    Nat Clin Pract Rheumatol; 2006 Jul; 2(7):346-7. PubMed ID: 16932716
    [No Abstract]   [Full Text] [Related]  

  • 2. The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis.
    Kavanaugh A; Cohen S; Cush JJ
    J Rheumatol; 2004 Oct; 31(10):1881-4. PubMed ID: 15468347
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cost effectiveness of pharmaceutical innovations. Health economic aspects of rheumatoid arthritis treatment with TNF-alpha antagonists].
    Kulp W; Greiner W; Graf von der Schulenburg JM
    Pharm Unserer Zeit; 2003; 32(5):420-5. PubMed ID: 14526463
    [No Abstract]   [Full Text] [Related]  

  • 4. Biologic therapy for early rheumatoid arthritis: the latest evidence.
    Castro-Rueda H; Kavanaugh A
    Curr Opin Rheumatol; 2008 May; 20(3):314-9. PubMed ID: 18388524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintaining and optimising anti-TNF therapy.
    Somerville M
    Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
    [No Abstract]   [Full Text] [Related]  

  • 6. PHARMAC responds on TNF inhibitors for inflammatory arthritis.
    Metcalfe S; Moodie P; Grocott R; Wilkinson T
    N Z Med J; 2005 Dec; 118(1227):U1799. PubMed ID: 16372039
    [No Abstract]   [Full Text] [Related]  

  • 7. Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment?
    Buch MH; Emery P
    Nat Clin Pract Rheumatol; 2006 Jun; 2(6):288-9. PubMed ID: 16932704
    [No Abstract]   [Full Text] [Related]  

  • 8. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-tumor necrosis factor agents are mostly used in patients with established rheumatoid arthritis compared to early disease -- a reflection of adequate clinical practice.
    Haraoui B
    J Rheumatol; 2009 Aug; 36(8):1561-2. PubMed ID: 19671804
    [No Abstract]   [Full Text] [Related]  

  • 10. [Stable remission of early active rheumatoid arthritis treated with etanercept (Enbrel)].
    Kaliterna DM
    Reumatizam; 2008; 55(2):60-1. PubMed ID: 19024277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic issues with new rheumatologic therapeutics.
    Kavanaugh A
    Curr Opin Rheumatol; 2007 May; 19(3):272-6. PubMed ID: 17414954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Saxne T; Larsson L; Geborek P
    Arthritis Rheum; 2004 Sep; 50(9):3049-50; author reply 3050-1. PubMed ID: 15457477
    [No Abstract]   [Full Text] [Related]  

  • 13. Subsidised access to TNF alpha inhibitors: is the rationale for exclusion of rheumatoid-factor-negative patients defensible?
    Lu CY; Williams KM; March L; Bertouch JV; Day RO
    Med J Aust; 2004 Oct; 181(8):457; discussion 457-8. PubMed ID: 15487967
    [No Abstract]   [Full Text] [Related]  

  • 14. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
    Redlich K; Schett G; Steiner G; Hayer S; Wagner EF; Smolen JS
    Arthritis Rheum; 2003 Dec; 48(12):3308-19. PubMed ID: 14673982
    [No Abstract]   [Full Text] [Related]  

  • 15. Do all drugs and treatments for rheumatoid arthritis have the same efficacy?
    Weisman MH
    Nat Clin Pract Rheumatol; 2008 Jun; 4(6):298-9. PubMed ID: 18431369
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical image: hidden costs of anti-tumor necrosis factor alpha therapy.
    Mulherin D; Sheeran TP
    Arthritis Rheum; 2003 Mar; 48(3):868. PubMed ID: 12632461
    [No Abstract]   [Full Text] [Related]  

  • 17. [Basic therapeutic and immunosuppressive drugs in rheumatoid arthritis. No fear of "heavy weapons"].
    Krüger K
    MMW Fortschr Med; 2002 Aug; 144(33-34):25-30. PubMed ID: 12380140
    [No Abstract]   [Full Text] [Related]  

  • 18. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade: comment on the article by Buch et al.
    Schiff MH
    Arthritis Rheum; 2005 Jan; 52(1):364-5; author reply 365. PubMed ID: 15641081
    [No Abstract]   [Full Text] [Related]  

  • 19. [Rheumatoid arthritis: early aggressive therapy including biologicals -- pro].
    Rubbert-Roth A
    Dtsch Med Wochenschr; 2005 Aug; 130(33):1900. PubMed ID: 16118736
    [No Abstract]   [Full Text] [Related]  

  • 20. [Recommendations of the German Society of Rheumatology for therapy with tumor necrosis factor inhibitors. Pharmacotherapy Committee of the German Society of Rheumatology].
    Z Rheumatol; 2000 Aug; 59(4):291-2. PubMed ID: 11013988
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.